National

Plasma Trials For Coronavirus Treatment To Begin In Delhi, Informs Kejriwal

Delhi Chief Minister Arvind Kejriwal on Thursday informed that the state has got an approval from the centre to conduct clinical trials of plasma-therapy to treat critically ill Covid-19 patients.

New Delhi| Delhi Chief Minister Arvind Kejriwal on Thursday informed that the state has got an approval from the centre to conduct clinical trials of plasma-therapy to treat critically ill Covid-19 patients. The therapy is only meant for coronavirus patients who are either on a ventilator or critically ill.

“Trial of Plasma Enrichment technique will begin in the next three or four days. If successful, we can save the lives of serious COVID-19 patients,” Arvind Kejriwal said.

Plasma therapy involves transfusion of plasma, from a patient who was earlier infected by the coronavirus but recovered later, to someone who’s currently critically ill because of coronavirus. The flood of the recovered patient is rich in antibodies that can help a critical patient recover.

The condition for a donor is the person must have tested negative twice after being infected, then kept in isolation of 14 days and still showed no symptoms.

“The ICMR is not a body for giving approvals. We have put out our protocols. Whoever works with our protocols, we will work with them. Others can approach department for separate clinical trial,” The Indian Council of Medical Research (ICMR) said today at the daily briefings of Health Ministry on Covid-19.

But the plasma therapy trials require approval from Drug Controller of India. To conduct this process, relaxation in blood donation norms is necessary.

Kerala and Maharastra too had sought approval from the centre to conduct plasma therapy trials.

 

Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.

Related posts